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Abstract
5–Hydroxymethylcytosine (hmC) was recently detected as the sixth base in mammalian tissue at so far controversial levels.
The function of the modified base is currently unknown, but it is certain that the base is generated from 5-methylcytosine
(mC). This fuels the hypothesis that it represents an intermediate of an active demethylation process, which could involve
further oxidation of the hydroxymethyl group to a formyl or carboxyl group followed by either deformylation or
decarboxylation. Here, we use an ultra-sensitive and accurate isotope based LC-MS method to precisely determine the levels
of hmC in various mouse tissues and we searched for 5–formylcytosine (fC), 5-carboxylcytosine (caC), and 5–
hydroxymethyluracil (hmU) as putative active demethylation intermediates. Our data suggest that an active oxidative
mC demethylation pathway is unlikely to occur. Additionally, we show using HPLC-MS analysis and immunohistochemistry
that hmC is present in all tissues and cell types with highest concentrations in neuronal cells of the CNS.
Citation: Globisch D, Mu ¨nzel M, Mu ¨ller M, Michalakis S, Wagner M, et al. (2010) Tissue Distribution of 5-Hydroxymethylcytosine and Search for Active
Demethylation Intermediates. PLoS ONE 5(12): e15367. doi:10.1371/journal.pone.0015367
Editor: Anna Kristina Croft, University of Wales Bangor, United Kingdom
Received September 17, 2010; Accepted November 11, 2010; Published December 23, 2010
Copyright:  2010 Globisch et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Funding was received from the following sources: the excellence cluster CiPSM, the SFBs 646 and 749, the Fond der Chemischen Industrie and Bayer
Schering Pharma AG. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: Funding was received from Bayer-Schering Pharma AG, which does not alter the authors’ adherence to the policies of PLoS ONE.
* E-mail: Thomas.carell@cup.uni-muenchen.de
. These authors contributed equally to this work.
Introduction
In 2009 it was discovered that the genetic material contains
aside from the nucleobases A, C, G, T, and 5-methylcytosine (mC)
the additional sixth base 5-hydroxymethylcytosine (hmC) [1,2].
Whereas it is well established that mC is a crucial epigenetic
marker [3], the function of the sixth base hmC is currently
unknown, but it is speculated that it is involved in epigenetic
regulation events or in active demethylation processes [4,5,6,7,8].
It was discovered that the base is generated from mC as precursor
via oxidation (hydroxylation) by members of the TET enzyme
family [2,9]. These TET enzymes are Fe(II)-dependent a-
oxoglutarate dioxygenases, which utilize molecular oxygen to
hydroxylate alkyl groups to hydroxymethyl functionalities via a
radical based mechanism [10]. It is currently hypothesized that
hmC could be a base involved in epigenetic modulation of gene
activity. The fact that hmC was also discovered in embryonic stem
cells (ES cells) and seems to play an important role in ES cells self-
renewal supports this hypothesis [9].
The base was originally detected in several tissues with the
highest levels in mammalian brain. In brain tissues, between 0.4%
and 0.7% of all dC bases were found to be converted into hmC
[1]. These values are in good agreement with a recent, more
detailed LC-MS study developed in our laboratory [11]. The
amount of hmC in other tissues was initially found to be small with
levels up to 0.1% but more precise quantification could not be
obtained due to the sensitivity limitations associated with the early
detection method. In an alternative attempt to achieve better
information about the hmC content, an enzymatic approach was
taken in which UDP-[
3H]glucose was used as a marker, which was
transferred onto hmC with the help of a specific glucosyltransfer-
ase. This assay provided hmC values far higher than those
reported earlier [12].
hmC could in principle directly modulate the binding of
proteins to DNA also during epigenetic regulation processes. For
example it was shown that methyl-CpG binding protein 2
(MeCP2) no longer binds to the corresponding sequences when
mCs were converted to hmCs in CpG sequences [13]. Alterna-
tively, it could function as an intermediate in active oxidative
demethylation (Figure 1) [14]. Oxidation of the hydroxymethyl
group to a formyl group would yield 5-formylcytosine (fC) which
could expel formic acid and react to C. Another possibility would
be further oxidation of hmC to 5-carboxylcytosine (caC) which
possesses a carboxyl group and would enable quick decarboxyl-
ation to regenerate dC (Figure 1). Nature’s most proficient
enzyme orotate decarboxylase catalyzes a similar reaction in which
orotate is decarboxylated to uridine [15]. Similar oxidation and
decarboxylation reactions are known for thymine in the
pyrimidine salvage pathway of certain eukaryotes [16,17,18].
Alternatively, hmC or its deamination product hmU could be
substrates of specialized DNA glycosylases [6,19,20,21]. Recent
observations that epigenetic reprogramming is associated with the
activation of base excision repair (BER) pathways support this
hypothesis [22,23]. During preparation of this manuscript a review
was published, which independently postulated these two putative
pathways for active DNA demethylation [24].
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In order to test the idea that hmC is an intermediate of such an
oxidative demethylation pathway and to shine light on the
distribution of hmC in mammalian tissues we applied an isotope
based HPLC-MS method to quantify hmC and to detect the
presence of fC, caC, and hmU in various tissues. Mass spectrometry
is a highly sensitive detection method that is, however, not
quantitative. (In certain cases mass spectrometry was used for
quantification of nucleosides [25]). Using stable isotope-labeled
reference compounds, which have the same chromatographic and
ionization properties but different molecular weights, turns MS into
a quantitative method [11,26,27,28]. By comparing the integrals of
the individual mass signals of the natural compound (amount to be
determined) and labeled compound (known amount) and subse-
quent application of calibration curves (Figure S1) very precise
quantification of the natural compound is achieved.
Synthesis of modified cytosine derivatives
The syntheses of the putative intermediates fC, caC, and hmU are
depicted in Figure 2. Starting point was dC, which was first
iodinated at position 5 and subsequently TBS protected to yield 1
[29]. A Pd-catalyzed carbonylation with Bu3SnH gave formylated
compound 2. This reaction proceeded in excellent yield even in the
presence of the unprotected amine at position 4. Deprotection of 2
with HF in pyridine generated fC. hmC was easily obtained after
reduction of 2 and subsequent deprotection of the TBS groups. Here,
addition of a Lewis acid [30] was essential, because simple reduction
using NaBH4 resulted mainly in decomposition of the starting
material, presumably because the hydride added to the position 6 of
intermediate 2. For the synthesis of the isotope-labeled standard[D2]-
hmC for mass spectrometric analyses Bu3SnD and NaBD4 were used
in the formylation and reduction reactions, respectively (for details
refer to the Text S1 and for a protective group free synthesis see
Figure S2). For the synthesis of caC we converted iodine 1 to a
TMS-ethanol-ester in a Pd-catalyzed reaction to yield compound 3
and subsequentlycleaved the protective groups.Fullyprotected 4was
synthesized according to a literature procedure and converted to
hmU with HF?pyridine [11].
HPLC-MS Quantification of hmC and mC in Mammalian
Tissue
Using the LC-MS method, we quantified the levels of hmC and
mC in parallel using the isotope-labeled derivative [D2]-hmC.
This reference compound is labeled to a very high extent (.99%),
which further enhances quantification accuracy of small amounts
of hmC allowing us to determine the content of hmC in any tissue
very precisely. For the study we isolated DNA from a variety of
different mouse tissues [11]. The isotope-labeled compound [D2]-
hmC and the obtained mixture was analyzed by HPLC-MS using
a sensitive MS-detector (Thermo Scientific LTQ Orbitrap XL). The
workflow of our method is illustrated in Figure 3. The
distribution of hmC and mC in different mouse tissues is depicted
in Figure 4A and 4B. We measured uniform amounts of mC
that represent 4.3060.22% of dG in all tissues in agreement with
previous reports [11,30,31]. The only exception is nasal epithelia
with a slightly lower value. To our surprise we found that hmC is
present in all investigated tissues at significant quantities. More
Figure 1. Putative demethylation pathways. Depiction of the known cytosine modifications mC and hmC and of the putative oxidative
‘‘demethylation’’ intermediates fC and caC. The base excision repair (BER) pathway is a second possible demethylation pathway via the intermediate
hmU.
doi:10.1371/journal.pone.0015367.g001
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strongly in contrast to the stable amounts of mC. Three different
classes of tissue are clearly distinguishable. The highest levels
(0.3%–0.7%) of hmC are detected in DNA isolated from the
central nervous system (CNS). The spinal cord, which is not a
direct part of the brain, also belongs to hmC rich tissues with a
value of 0.47%. These data strengthen the observation that
neuronal tissues contain the highest levels of hmC. DNA extracted
from kidney, nasal epithelium, bladder, heart, skeletal muscle, and
lung has medium hmC values from 0.15%–0.17%. DNA from
liver, spleen, and the endocrine glands (testes and pituitary gland)
possess the lowest amounts of hmC with levels ranging from
Figure 2. Synthesis of [D2]-hmC and the putative intermediates fC, caC, and hmU. a) CO, PPh3,P d 2(dba)3?CHCl3,B u 3SnH, 97%, with Bu3SnD
49%, b) HF pyridine, 75%, c) NaBD4, CeCl3?7H2O, 21%, d) TBAF, 51%, e) CO, TMS-Et-OH, DIPEA, Pd2Cl2(MeCN)2, 52%, f) TBAF, 69%, g) Reference [11] h)
HF?pyridine, 70%. All reactions could also be carried out in a protective group free manner but resulted in reduced yields and tedious workups (see
Figure S2 for details).
doi:10.1371/journal.pone.0015367.g002
Figure 3. Workflow of the HPLC-MS quantification method. DNA is extracted from any kind of tissue and subsequently enzymatically
digested to the nucleosides. Subsequently, a known amount of the stable isotope-labeled standard nucleoside is added. In the HPLC-MS analysis one
signal for the natural (light) and one for the synthetic (heavy) compound is detected in each experiment. Quantification is performed by comparing
the integrals of the specific high resolution ion current of the natural compound (amount to be determined) with their corresponding heavy atom
labeled derivative (known amount).
doi:10.1371/journal.pone.0015367.g003
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less hmC compared to tissues with medium levels and up to 20
times less than cerebral cortex as part of CNS. Interestingly, the
pituitary gland, which is located in the brain, has a low hmC value
of only 0.06%, supporting the hypothesis that high hmC content is
related to neuronal function, rather than mere localization in the
brain. In contrast to mC, the hmC amounts are tissue specific.
Immunohistology experiments
In order to further validate our quantification data and to
determine the exact location of hmC in tissues more precisely we
performed immunostaining experiments with a commercially
available hmC-specific antibody [9,11]. The results are depicted
in Figure 5. The pictures show, that the sixth base is clearly
located in the cell nuclei as expected. Upon addition of a hmC
containing capturing oligonucleotide the signal obtained from the
nuclei is reduced showing that the antibody is specific for hmC. It
is evident that the highest amounts of hmC are present in the
nuclei of the hippocampus and that kidney is stained with a clearly
higher intensity than liver, which supports our HPLC-MS results
(See Figure S3 for further immunohistology experiments).
Furthermore, virtually all cells contain hmC. Interestingly,
whereas hmC is equally distributed in liver and kidney, its location
in the hippocampus is very diverse. The highest levels are detected
in the fully differentiated neurons of the dentate gyrus. Cells
located in the subgranular zone between dentate gyrus and hilus
show clearly reduced staining in line with reduced hmC levels
(Figure 6). This area contains the neural progenitors known to
generate new neurons in the hippocampus of adult mice [32,33].
Putative demethylation pathways
To seek evidence if hmC is part of an oxidative demethylation
pathway we investigated if the DNA samples contain fC and caC
as putative downstream intermediates. Using the LC-MS method
we first determined the detection limit to be in the low picomolar
range, even with the background of canonical nucleosides in
digested samples (Figure 7B). This shows that even traces of these
compounds at levels 70–350 times lower than the base hmC itself
could unambiguously be detected. The HPLC-chromatogram of
caC, hmC, hmU, mC, and fC is shown in Figure 7A. In addition
we maximized the amount of digested DNA applicable for HPLC-
MS analysis. For these experiments, we typically used 70–160 mg
of DNA isolated from the tissues. The DNA was again
enzymatically digested and analyzed. For comparison, the
previous experiments were performed using ten times less DNA.
Despite this, neither fC nor caC could be detected. The results
show that if present, fC does not reach levels above 7?10
24% of all
nucleosides and 0.3% of hmC and caC does not reach levels above
3.5?10
23% of all nucleosides and 1.4% of hmC. Our results show
that either an oxidative active demethylation pathway does not
exist, that intermediates are short lived or that they are not
released from the enzymatic complex.
Another potential active demethylation pathway could involve
the base excision repair (BER) pathway of cells (Figure 1) either
directly or via hmU [21]. Thus we investigated the presence of
hmU, which could be formed by deamination of hmC by an
analog of activation induced cytidine deaminase (AID) [6]. hmU is
known to be a substrate for the glycosylase SMUG1 [19,20]. It can
be speculated that deamination of hmC to give hmU could be a
signal for repair driven removal of mC via hmC. Again our
HPLC-MS method did not provide any evidence for the presence
of this compound in the digested DNA making such a mechanism
equally unlikely (Figure 7B).
Discussion
The role of mC in epigenetic regulatory processes is today quite
well understood. The introduction and heredity of methylation
patterns by DNA methyltransferases is an established fact.
Figure 4. Quantification of hmC and mC in mouse tissue. A) Values of hmC in % of dG. B) Values of mC in % of dG. A)+B) Data represent values
for each tissue of at least two mice with standard deviation (SD) (See Table S1 for details). Light-colored bars represent data from our earlier study
[11].
doi:10.1371/journal.pone.0015367.g004
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code is still controversially discussed [24]. Thus it is not surprising
that the discovery of hmC and the modifying TET enzymes in
2009 caused significant excitement. To elucidate the function of
hmC in mammalian tissue, the knowledge of its distribution could
provide valuable information.
How is hmC distributed in mammalian tissues?
Our quantification results in different tissues show that hmC is
present in every tissue investigated. However, our obtained values
are in disagreement with the recently determined higher levels
measured using an enzymatic method [12] but they are in good
agreement with those levels reported initially based on radioactive
Figure 5. Immunolocalization of hmC in mouse hippocampus, kidney, and liver. Scale bar: 200 mM. Left column: mouse tissues stained
with anti-hmC (green). Middle column: mouse tissues stained with anti-hmC (green) and Hoechst 33342 (blue) for nuclear staining. Right column:
Bright field pictures of corresponding tissue. In every second row 2 mM hmC-DNA were added to compete the anti-hmC staining signal out.
doi:10.1371/journal.pone.0015367.g005
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at that time close to the detection limit of the method [1]. By
employing our HPLC-MS method, that uses an internal standard
and calibration curves, we solve this scientific controversy and
show that hmC is present in cells in levels between 0.03% and
0.69% of dG.
Our immunohistology data support the idea that oxidation of
mC to hmC is a process occurring in all cells. Interestingly, we
found indication in the dentate gyrus of the hippocampus that the
hmC levels are significantly lower in stem cell rich areas.
Is hmC an intermediate in active cytosine demethylation?
It was speculated that hmC could represent an intermediate of
an oxidative mC removal pathway. We proposed that hmC can be
further oxidized to fC and caC similar to the pyrimidine salvage
pathway or that it could be deaminated to hmU to be further
excised by BER enzymes. Based on our data, however, we can
exclude substantial oxidation of hmC to fC or caC or deamination
of hmC to result in hmU. This does not disprove that these
pathways do exist since we cannot exclude that the application of
more sensitive methods, such as HPLC-MS/MS may lead to the
discovery of these modifications in the future. In addition, if hmC
or hmU were excised directly from DNA, it should be possible to
detect these degradation products in urine [34]. But the data show
that these unavoidable intermediates do not accumulate to any
significant level, making it unlikely that such reactions occur at
large scale or that they are extremely short lived intermediates.
Materials and Methods
General methods
All non-aqueous reactions were performed using flame- or
ovendried glassware under an atmosphere of dry nitrogen.
Commercial reagents from Sigma-Aldrich or Acros were used as
received unless otherwise noted. Non-aqueous reagents were
transferred under nitrogen with a syringe or cannula. Solutions
were concentrated in vacuo on a Heidolph rotary evaporator.
Chromatographic purification of products was accomplished using
flash column chromatography on Merck Geduran Si 60 (40–
63 mM) silica gel (normal phase), Fluka silica gel 100 C18-Reversed
phase (15–35 mm), or preparative HPLC on a Merck-Hitachi system
(L-7150 pump, L-7420 detector) equipped with a Macherey Nagel
VP 250/32 Nucleosil 100-7 C18 column, 15.0 mL/min flow rate,
as indicated. Thin layer chromatography (TLC) was performed on
Merck 60 (silica gel F254) plates. Visualization of the developed
Figure 6. Immunolocalization of hmC in mouse hippocampus.
High magnification images of hmC immunoreactivity in the dentate
gyrus (DG) and the hilus of mouse hippocampus. A) Signal for anti-hmC
(green) and Hoechst 33342 nuclear dye (blue) B) Competition of anti-
hmC with 2 mM hmC-DNA. The scale bar marks 20 mm.
doi:10.1371/journal.pone.0015367.g006
Figure 7. Detection of potential demethylation intermediates caC, hmU, and fC. A) HPLC-chromatogram of the synthesized cytosine and
uracil modifications caC, hmC, hmU, mC, and fC as 29-deoxynucleosides showing excellent separation of the compounds. B) Detected values of the
potential intermediates as example in olfactory bulb. The red line indicates the detection limits of the modified nucleosides in enzymatically digested
DNA samples.
doi:10.1371/journal.pone.0015367.g007
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anisaldehyde staining.
1H and
13C NMR spectra were recorded in
deuterated solvents on Bruker ARX 300, Varian VXR400S, Varian
Inova 400 and Bruker AMX 600 spectrometers and calibrated to the
residual solvent peak. Multiplicities are abbreviated as follows: s =
singlet, d = doublet, t = triplet, q = quartet, m = multiplet.
13C-
NMR signals of carbons carrying deuterium atoms have been
determined by C-H correlation spectra (HMBC). ESI spectra and
high-resolution ESI spectra were obtained on the mass spectrom-
eter Thermo Finnigan LTQ FT-ICR. Acetonitrile (HPLC gradient
grade) for HPLC-ESI-MS analysis was purchased from VWR.
HCOOH (p.a. for mass spectrometry) was purchased from Fluka.
Mouse tissues from three male mice (C57BL/6N) were frozen in
liquid nitrogen right after sacrifice. Depending on the tissue type
each mouse supplied enough DNA for up to 4 measurements.
DNA extraction from mouse tissue
DNA isolation was performed on the basis of the QIAamp DNA
Mini Kit. Instead of column purification phenol extraction was
performed as outlined in the next paragraph. The RNA digest was
executed twice. All other steps were performed as described by the
manufacturer. For samples with more than 25 mg weight the
quantities of the reagents were increased accordingly. Tissue
samples were homogenized with PBS and a stainless steel bead in a
TissueLyser (Qiagen, 30 Hz, 2 min). ATL and proteinase K were
added and the solution was incubated. DNase-free RNase A (4 mL,
100 mg/mL) was added. After mixing the sample was incubated
and shaken (600 rpm) at rt for 5 min. A second portion of DNase-
free RNase A (4 mL, 100 mg/mL) was added and the mixture was
again incubated and shaken (600 rpm) at rt for 5 min. The tube
was centrifuged briefly and buffer AL was added. The sample was
mixed and incubated. Following this step the sample was no longer
processed on the basis of the QIAamp DNA Mini Kit.
The sample was distributed equally to two 2 mL reaction tubes,
if necessary. A 1/1 mixture of RotiHPhenol/chloroform (1 Vol.)
was added and the tube was shaken vigorously at rt for 5 min. The
tube was centrifuged (12100 g, 15 min) and the aq. layer was
collected. This procedure was repeated once. To the obtained aq.
layer chloroform (1 Vol.) was added and the tube was shaken at rt
for 1 min. After centrifugation (12100 g, 5 min) the aq. layer was
collected. During collection of the aq. layers special care was taken
to include the interphase. The sample was distributed equally to
two 2 mL reaction tubes, if necessary. Ethanol (3 Vol.) was added.
The sample was left to stand at rt for approximately 2 h. After
precipitation of the DNA the tube was centrifuged (12100 g,
30 min). The supernatant was discarded and the pellet was dried.
Subsequently, it was dissolved in water (100–400 mL). The solution
was centrifuged (12100 g, 30 min) and the supernatant was
collected.
Enzymatic digestion
For the enzymatic digestion DNA mixtures (4 to 10 mg in a final
volume of 100 mLH 2O) were heated to 100uC for 5 min to
denature the DNA and rapidly cooled on ice. Buffer A (10 mL,
300 mM ammonium acetate, 100 mM CaCl2, 1 mM ZnSO4,
pH 5.7) and nuclease S1 (80 units, Aspergillus oryzae) were added to
the mixture and incubated for 3 h at 37uC. Addition of buffer B
(12 mL, 500 mM Tris-HCl, 1 mM EDTA), antarctic phosphatase
(10 units), snake venom phosphodiesterase I (0.2 units, Crotalus
adamanteus venom) and incubation for further 3 h at 37uC completed
the digestion. Labeled nucleosides [D2]hmC and [D3]mC were
added, followed by centrifugation of the sample (12100 g, 15 min).
The supernatant was removed, the volume reduced to 100 mL and
measured with HPLC-ESI-MS. Each sample was analyzed at least
in duplicate with independent concentrations of the two
labeled nucleosides. The concentrations of standard solutions
were chosen to be in the expected range of the sample nucleoside
concentration.
HPLC-ESI-MS
The samples (100 mL injection volume) were analyzed by
HPLC-ESI-MS on a Thermo Finnigan LTQ Orbitrap XL and
chromatographed by a Dionex Ultimate 3000 HPLC system with a
flow of 0.15 mL/min over an Uptisphere120-3HDO column from
Interchim. The column temperature was maintained at 30uC.
Eluting buffers were buffer C (2 mM HCOONH4 in H2O
(pH 5.5)) and buffer D (2 mM HCOONH4 in H2O/MeCN 20/
80 (pH 5.5)). The gradient was 0 R 12 min; 0% R 3% buffer D;
12 R 60 min; 3% R 60% buffer D; 60 R 62 min; 60% R 100%
buffer D; 62 R 70 min; 100% buffer D; 70 R 85 min; 100 R 0%
buffer D; 85 R 95 min; 0% buffer D. The elution was monitored
at 260 nm (Dionex Ultimate 3000 Diode Array Detector). The
chromatographic eluent was directly injected into the ion source
without prior splitting. Ions were scanned by use of a positive
polarity mode over a full-scan range of m/z 200–1000 with a
resolution of 30.000. Parameters of the mass spectrometer were
tuned with a freshly mixed solution of adenosine (5 mM) in buffer
C. The parameters used in this section were sheath gas flow rate,
16 arb; auxiliary gas flow rate, 11 arb; sweep gas flow rate, 4 arb;
spray voltage, 5.0 kV; capillary temperature, 200uC; capillary
voltage, 12 V, tube lens 60 V.
Mass calibration curves
Mass calibration curves of the labeled and corresponding
unlabeled synthesized nucleosides were obtained at five different
concentration ratios. For each concentration an average value of
three independent measurements was determined (Figure S1).
Each labeled nucleoside solution was mixed with three solutions
with different concentrations of the corresponding unlabeled
nucleosides. The areas of labeled and unlabeled nucleosides of the
LC-MS measurements were determined using the Qualbrowser
program by extraction of the accurate mass with a mass filter
(Table S1) from the total ion current (TIC). The linear fits of the
determined area ratios over the amount ratios gave R
2-values of
minimum 0.9987 for mC and 0.9997 for hmC. The linear
equations were used for calculation of the exact nucleoside
contents in genomic DNA samples. Synthetic labeled nucleosides
were added to the enzymatically digested nucleoside mixture and
the areas of labeled and unlabeled nucleosides were determined as
described above. The amount of each nucleoside was calculated
from the obtained area ratios and the linear fit equations of the
calibration curves. Determination of the precise amounts of mC
and hmC by the described isotope-labeled mass spectrometric
method and determination of the precise amount of dG by
integration of the UV/vis signal of the HPLC chromatogram
enabled calculation of the exact percentage of mC and hmC to dG
[11]. We have chosen dG as a standard, because it forms base
pairs with all three cytosine derivatives dC, mC and hmC.
Immunohistochemistry
Coronal cryosections (12 mm) from 12 week old C57-BL6/N
mice were rehydrated in phosphate buffered saline (PBS), fixed
(10 min, 4% paraformaldehyde in PBS, pH 7,4), treated with 2N
HCl in PBS (20 min) and incubated for 16 hours (4uC) with
primary antibodies in 5% chemiblocker (Millipore, Germany) and
0.3% Triton X-100 in PBS. The primary antibody used was:
rabbit anti-5-hydroxymethylcytosine (hmC, 1:500, Active Motif,
Belgium). For secondary detection we used goat Alexa488 anti-
5-hmC and Demethylation Intermediates
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were counterstained with Hoechst 33342 (5 mg/mL, Sigma,
Germany) and sections were mounted with aqueous mounting
medium (PermaFluor, Beckman-Coulter, USA). Tissues were
analyzed using a Zeiss Axioscope epifluorescence microscope
equipped with a HBO 100 mercury arc lamp, appropriate filters
equipped with an MRc ccd camera (Zeiss, Germany). Laser
scanning confocal micrographs were collected using a LSM 510
meta microscope (Carl Zeiss, Germany).
Supporting Information
Figure S1 Mass calibration curves of the nucleosides
mC and hmC. Linear fits of five data points represent perfect
linearity with R
2-values of 0.9987 for mC and 0.9997 for hmC.
(TIF)
Figure S2 Protective group free synthesis of putative
cytosine derivatives. a) I2, mCPBA, 63% b) CO, Bu3SnH,
Pd2(dba)3, 35% c) NaBH4, CeCl3?7H2O, 53% d) TMS-Et-OH,
CO, DIPEA, PdCl2(MeCN)2, 22% e) HF?pyr, 11%. The putative
oxidative catabolites of hmC could also be synthesized in a
protective group free manner. However, these syntheses suffer
from lower yields and the workup procedures get considerably
more tedious than with the TBS-protected compounds. dC can be
converted to 5 by oxidative iodination using iodine and mCPBA.
Subsequent palladium catalyzed formylation with CO and
Bu3SnH in DMF as solvent gave fC in 34% yield. Subsequent
Luche reduction furnished hmC. 5 could be converted to 6 in a
carbonylating coupling of the iodine with TMS-ethanol. Final
cleavage of the ester with F
- yields ethene, TMSF and caC.
(TIF)
Figure S3 Immunolocalization of hmC in mouse kid-
ney, liver, and heart. Scale bar: 20 mm. Mouse tissues stained
with anti-hmC (green), Hoechst 33342 nuclear staining is shown in
blue. A+G+M) anti-hmC staining. B+H+N) anti-hmC (green) and
Hoechst 33342 (blue). D+J+P) The anti-hmC staining signal was
competed out by 2mM hmC-DNA. E+K+Q) The anti-hmC
staining signal was competed out by 2mM hmC-DNA. C+F+I+
L+O+R) Bright field pictures of the used tissues. gl: glomerolus, s:
sinusoid.
(TIF)
Table S1 Nucleoside percentages of mC and hmC to dG
in different mouse tissues (Figure 2 in main text). Each
mouse tissue is listed with the determined values, the standard
deviation (SD) and the relative standard deviation (RSD). The
average mouse values are listed in the last column. For muscle, the
DNA of mouse 1+2 was mixed due to a low amount of DNA. The
applied mass ranges of analyzed nucleosides are shown as well.
(PDF)
Text S1 Supporting text.
(PDF)
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